Our mission “To help women keeping a healthy intimate and vaginal balance by providing excellent and innovative products that are easy to use and when applicable, with a scientific background ” ellen ® Female intimate health Prevention and Protection Restoration and Balance Proven Probiotics - Lacto Naturel

2013 was a lost year for Ellen 41% 31% 6% Source: Annual reports

2000 Ellen AB was founded 2001 Patent for LN® bacterial strains (valid until 2021) 2002 Patent for production process (valid until 2022) 2003 The probiotic tampon ellen® launch in Sweden 2007 ellen® launch in Austria and France 2008 Medical Device product in EU- ellen® launch in Germany Ellen Asia Ltd was founded 2011 Ellen agreements in 37 markets & launch in 13 countries 2013 ellen® Probiotic Intimate creme was launched Milestones of the company´s development

 Dismissed staff are: Ellen has no longer a general secretary Research and development manager as well as brand manager have been dismissed  Product development is a strategic issue and resources for development of new products became part of the sales and marketing manager  External resources have been added to secure the ISO certificate instead of full time employment A cost cutting program has been initiated and three persons have been dismissed

The new organisation of Ellen CEO Ingrid Atteryd Heiman CEO Ingrid Atteryd Heiman Distributors/Partners Suppliers Consultants Scientific Board Liao Qinping, Prof. Beijing, China Gerd Neumann,Prof. Dr. Hamburg, Germany Carl Påhlson,Prof Molecular biology, Sweden Lars-Olof Berg, MSc, Microbiologist, Sweden Dr Dvorak, MD, PhD. Czech Republic Dr Sophia Ehrström, PhD. Sweden Scientific Board Liao Qinping, Prof. Beijing, China Gerd Neumann,Prof. Dr. Hamburg, Germany Carl Påhlson,Prof Molecular biology, Sweden Lars-Olof Berg, MSc, Microbiologist, Sweden Dr Dvorak, MD, PhD. Czech Republic Dr Sophia Ehrström, PhD. Sweden Board of Directors Stefan Appelgren, Chairman Mikael Lövgren Ingrid Atteryd Heiman Anders Boquist Board of Directors Stefan Appelgren, Chairman Mikael Lövgren Ingrid Atteryd Heiman Anders Boquist Support Ström & Gulliksson Mazars SET LA Groth Ants MAQS Law firm Support Ström & Gulliksson Mazars SET LA Groth Ants MAQS Law firm Share holders CFO Emilie Andersson CFO Emilie Andersson QA/RA Peter Landvall QA/RA Peter Landvall Production Ylva Winberg Production Ylva Winberg Marketing & Sales Annika Sahlin Pohl Marketing & Sales Annika Sahlin Pohl Logistic ass. Charlotta Baringe Logistic ass. Charlotta Baringe

 Close co-operation with our partners  Strategic marketing and sales support to our distributors  Global brand communication – when possible  Sharing information to encourage communication and take advantage of good ideas and initiatives  Product development within Female intimate health Ellen has a distributor strategy worldwide

1.Pharmacies 2.Parapharmacies 3.Drugstores 4.Healthfood stores 5.Web-shops Sales channels are mainly pharmacies and drugstores

 Close co-operation with our partners  Partners are divided into two groups – strategic partners and partners with growth potentials  Increased strategic marketing and sales support to our partners  Global brand communication – when possible  Sharing information to encourage communication and take advantage of good ideas and initiatives  Create and support an international web-shop Ellen prioritise to give support to our existing partners

Our Partners are twelve altogether Our strategic partners are: IPRAD Ellen Vertriebs Navamedic Our partners with growth potentials are: Transmeri, Finland Bio-Tech, Hungary Holbex, Poland Casen Recordati, Spain S&D Pharma, Czech Republic and Slovakia Sante HM, Romania Tosama, Balkan countries Ellen Asia

The distributors Iprad and Ellen Vertriebs dominate the sales 41% 31% 10% 6% 12% IPRAD (France, Belgium) Ellen Vertriebs Germany, Austria, Switzerland) The Nordic countries Denmark, Finland, Norway, Sweden, Webshop S&D Pharma Czech Republic, Slovakia Others Sales, interim report first half of 2014

Operating expenses first half of 2014 are less then 2013 and % 31% 6% Source: Interim report first half of Jan - June Net sales Operating expenses Operating loss EBITDA EBITDA adjusted for restructuring expenses Loss for the period Gross margin43%41% Number of staff4,57,56,5

MAN mouthgastrointestinal tract - FEMALE mouthgastrointestinal tractvaginal cavity Our healthy body – billions of natural lactobacilli exist in;

External factors Sexual activity Contraceptive choice Extended hygiene, intimate shaving Use of antibiotics Internal factors Genetic inheritance Hormonal changes Age, Pregnancy, Menstrual cycle 25% of women suffers from imbalance in their intimate area - “100 million women in Europe” Causes can be:

ellen® Probiotic Tampon - a Dual Action Medical Device/Consumer product Probiotics Menstruation protection  Restores/maintains a healthy vaginal bacterial flora  Balances the vaginal pH  Promotes vaginal health  Comfortable, high quality menstrual protection 2 in 1 - Double action

The process and the probiotics strains are protected by patents Good clinical results which shows LN ® strains efficacy and safety - 6 clinical studies - 3 in vitro studies Process for production of an absorbing sanitary article comprising lactic acid producing bacteria - Patented until in 21 markets Lactic acid producing bacteria for use as probiotic organisms in the human vagina - Patented until in 19 markets

 Lactobacillus gasseri LN40  Lactobacillus rhamnosus LN113  Lactobacillus fermentum LN99 The patented LN strains are three These strains Belong to common vaginal Lactobacillus species They are isolated from healthy women’s vaginal flora (Lund University, Sweden) They are genetically stable They are the active ingredients in ellen® Probiotic tampon and intimate creme

In vitro studies of LN strains shows LN strains produce antimicrobial substances  Produce lactic acid+  Lower the pH+  Produce Hydrogen Peroxide (H 2 O 2 )+  Inhibit urogenital pathogens Escherichia coli, Streptococcus agalactiae, Enterococcus faecalis, Staphylococcus aureus +  Inhibit yeast Candida albicans + Adhere excellent to epithelial cells+

LN strains – Clinically proven  Administered vaginally (tampons and capsules) ↓  Colonizes the vagina  Reduces vaginal discomfort (itching & irritation)  Reduces malodorous discharge  Improved cure rate  Reduces recurrences of BV and CV  Safe to use

Studies of ellen® products ellen® Probiotic tampon Clinical Study 1: 1992, Sweden (20 women) Clinical Study 2: 2001, Sweden (16 women) Clinical Study 3: 2006, Sweden/Norway/Finland (255 women) Clinical Study 4: 2012, Ukraine (40 women) __________________________________________________ LN strains (vaginal capsules) Clinical Study 1: 2010, Sweden (95 women) _________________________________________ ellen® Intimate Crème Clinical Study 1: 2013, Sweden (95 women) Under publication Consumer study 1: 2012, Sweden (29 women) Consumer study 2: 2013, Sweden (92 women) ______________________________________________

Ellen Probiotic tampon is the only one in the world  Tampon with natural lactobacilli  Three different sizes  With or without applicators

Recommendations  Minimum 3 tampons per day during 3 days in a period  Choose the right size according to bleeding  All women who are menstruating  Women who are in danger of getting recurrant vaginal infections  All women who just used antibiotics of any kind  When swimming and frequent washing

Add-on product – for campaigns or regular Monthly Pack! Probiotic tampons + regular tampons Normal size All tampons you need in one menstruation! Test sales in Germany Available now!

ellen® Probiotic Intimate Crème For a dry and sensitive external intimate area  2 in 1 – Natural lactobacilli and Natural fats/oils  No preservatives  No perfume  No water

Double action cosmetic product Ointment Moisturize  Softens the external mucus membranes  Prevent dryness  Give a natural and fresh feeling Helps to maintain a natural microbial flora  Contribute to the body’s natural bacterial flora and barrier (hydrolipidic film) in the external intimate area Natural ingredients

Target group  Dryness in the intimate area  Have a sense of not being fresh  Bad odour  Protection against unwanted bacteria  Fertile women  Menopausal and postmenopausal women

Proffessional feedback Gynecologists comments:  Unique - without water, perfume and preservatives  Lactobacilli - no other crème on the market containing probiotic bacteria, specific for the vaginal area  Protection - very important to protect all 3 entrances (Urinary tract, Vagina and Anal opening) from bad bacteria  Relief - almost immediate effect when it comes to symptoms

Summary – Why ellen® Probiotic Intimate creme?  Can be used by all women – fertile, active, young, menopausal, pregnant etc.  Protective Barrier against unwanted bacteria  Unique with proven probiotics, LN complex  Swedish Quality, invention and production  Tested and proven  Natural and free from preservatives, perfume, estrogen and water  Can be used in combination with antibiotics and antimycotics  Complement to the probiotic tampons

New products resently developed is an intimate wash foam  Salvia Officinalis (Sage oil)  Anti-inflammatory  Prevents from bad odour  Eco cert approved  Lactic Acid  pH-balanced (6)  Foam  Less water – do not dry out the skin  Lasts longer  Gentle against the mucosa Good combination with the Intimate creme Natural & Eco-Friendly Dermatologically tested pH: In healthy Vagina ≈ 4 Neutral = 7 (To high value makes growth of pathogens)

Why Intimate deo?  Salvia Officinalis (Sage oil)  Anti-inflammatory  Anti odour – prevents sweat formation  Eco cert approved  Lactic Acid  pH-balanced (5)  Deo  24 hour effect  Refreshing & Gentle  Free from Aluminium  Quick absorption Good combination with the Intimate creme Natural & Eco-Friendly Dermatologically tested We are all sweating also in the intimate area!

Thank you! Ingrid Atteryd Heiman tfVD, Ellen AB Emilie Andersson CFO, Ellen AB